Dr. Dr. Cloughesy is a Professor of Neurology at the David Geffen School of Medicine at UCLA. He received his BA degree with Honors in Chemistry in 1983 at University of California, Santa Barbara, and his MD degree in 1987 at Tulane University. He completed his Neurology Residency at University of California, Los Angeles and fellowships in Clinical Neurophysiology (UCLA 1991- 1992) and Neuro-Oncology (Memorial Sloan Kettering Cancer Center 1992).

Dr. Cloughesy is board certified in Neurology and Clinical Neurophysiology. He joined the faculty of the David Geffen School of Medicine at UCLA in 1992 with the Department of Neurology.

He is the director of the Neuro-Oncology Program at UCLA and the Director of the Henry Singleton Brain Cancer Research Program. He is a member of the Brain Research Institute and Jonsson Comprehensive Cancer Center at UCLA.

Dr. Cloughesy’s research has focused on clinical trials in brain cancer using targeted molecular therapies with novel clinical trial design and biomarkers in brain cancer.  He provided principal leadership for the approval of bevacizumab for recurrent glioblastoma. This was the first drug approved for recurrent glioblastoma in over 30 years.

He is recognized as a world expert in the brain cancer research and has been asked to lead several first-in-human studies to treat glioblastoma. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging, and molecular analysis to enhance translational research and has the goal of using biomarkers to provide individualized care for brain cancer patients. He has authored or co-authored over 200 peer-reviewed articles on brain cancer.